The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model

Moxifloxacin is under development for expanded use against Mycobacterium tuberculosis. Rifampin is a mainstay of therapy. We examined the interaction of moxifloxacin plus rifampin for log-phase and nonreplicating persister (NRP) organisms. For this evaluation, we employed our hollow-fiber infection...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Drusano, G. L., Sgambati, Nicole, Eichas, Adam, Brown, David L., Kulawy, Robert, Louie, Arnold
Format: Artigo
Idioma:Inglês
Publicat: American Society of Microbiology 2010
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2925073/
https://ncbi.nlm.nih.gov/pubmed/20802826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/mBio.00139-10
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars